« Return to News | R&D Trends | CROs/Service Providers

Charles River, Pfizer collaborate

Friday, March 4, 2011 02:19 PM

Charles River Laboratories has signed a marketing and distribution agreement with Pfizer to provide certain Pfizer-developed genetically modified research models to the global biomedical research community. Under this agreement, CRL will supply a number of pre-competitive, transgenic research models developed by Pfizer across a broad range of therapeutic areas, including neuroscience, diabetes and cardiovascular disease.

“The use of genetically modified research models continues to emerge as an important tool to allow scientists in their research to target specific disease states and genetic markers,” said Dr. Iva Morse, corporate vice president, global research model services at Charles River.

Rick Connell, vice president and worldwide head of the external research solutions center of excellence at Pfizer, said, “This agreement with Charles River aligns with Pfizer’s strategy to externalize our pre-competitive tools and assets to a broader community of scientists outside of Pfizer’s walls. We collectively share an interest in seeing science advance to enable the continued development of innovative medicines for patients.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.